GDC-0810 (ARN-810) - CAS 1365888-06-7
Catalog number: 1365888-06-7
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C26H20ClFN2O2
Molecular Weight:
446.91
COA:
Inquire
Targets:
Estrogen Receptor/ERR
Description:
GDC-0810, also known as ARN-810 and RG6046, an orally bioavailable Selective Estrogen Receptor Degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts.
Purity:
98%
Appearance:
Solid powder
Synonyms:
GDC0810; GDC 0810; GDC-0810; ARN810; ARN 810; ARN-810; RG6046; RG-6046; RG 6046.
Solubility:
Soluble in DMSO, not in water
Storage:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
MSDS:
Inquire
Shelf Life:
2 years if stored properly
Canonical SMILES:
O=C(O)/C=C/C1=CC=C(C=C1)/C(C2=CC3=C(NN=C3)C=C2)=C(CC)\C4=CC=C(C=C4Cl)F
1.Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer.
Xiong R;Zhao J;Gutgesell LM;Wang Y;Lee S;Karumudi B;Zhao H;Lu Y;Tonetti DA;Thatcher GR J Med Chem. 2017 Feb 23;60(4):1325-1342. doi: 10.1021/acs.jmedchem.6b01355. Epub 2017 Feb 10.
Resistance to the selective estrogen receptor modulator tamoxifen and to aromatase inhibitors that lower circulating estradiol occurs in up to 50% of patients, generally leading to an endocrine-independent ER+ phenotype. Selective ER downregulators (SERDs) are able to ablate ER and thus, theoretically, to prevent survival of both endocrine-dependent and -independent ER+ tumors. The clinical SERD fulvestrant is hampered by intramuscular administration and undesirable pharmacokinetics. Novel SERDs were designed using the 6-OH-benzothiophene (BT) scaffold common to arzoxifene and raloxifene. Treatment-resistant (TR) ER+ cell lines (MCF-7:5C and MCF-7:TAM1) were used for optimization, followed by validation in the parent endocrine-dependent cell line (MCF-7:WS8), in 2D and 3D cultures, using ERα in-cell westerns, ERE-luciferase, and cell viability assays, with 2 (GDC-0810/ARN-810) used for comparison. Two BT SERDs with superior in vitro activity to 2 were studied for bioavailability and shown to cause regression of a TR, endocrine-independent ER+ xenograft superior to that with 2.
2.Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.
Lai A;Kahraman M;Govek S;Nagasawa J;Bonnefous C;Julien J;Douglas K;Sensintaffar J;Lu N;Lee KJ;Aparicio A;Kaufman J;Qian J;Shao G;Prudente R;Moon MJ;Joseph JD;Darimont B;Brigham D;Grillot K;Heyman R;Rix PJ;Hager JH;Smith ND J Med Chem. 2015 Jun 25;58(12):4888-904. doi: 10.1021/acs.jmedchem.5b00054. Epub 2015 May 22.
Approximately 80% of breast cancers are estrogen receptor alpha (ER-α) positive, and although women typically initially respond well to antihormonal therapies such as tamoxifen and aromatase inhibitors, resistance often emerges. Although a variety of resistance mechanism may be at play in this state, there is evidence that in many cases the ER still plays a central role, including mutations in the ER leading to constitutively active receptor. Fulvestrant is a steroid-based, selective estrogen receptor degrader (SERD) that both antagonizes and degrades ER-α and is active in patients who have progressed on antihormonal agents. However, fulvestrant suffers from poor pharmaceutical properties and must be administered by intramuscular injections that limit the total amount of drug that can be administered and hence lead to the potential for incomplete receptor blockade. We describe the identification and characterization of a series of small-molecule, orally bioavailable SERDs which are potent antagonists and degraders of ER-α and in which the ER-α degrading properties were prospectively optimized. The lead compound 11l (GDC-0810 or ARN-810) demonstrates robust activity in models of tamoxifen-sensitive and tamoxifen-resistant breast cancer, and is currently in clinical trials in women with locally advanced or metastatic estrogen receptor-positive breast cancer.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Estrogen Receptor/ERR Products


CAS 1847-63-8 Nafoxidine HCl

Nafoxidine HCl
(CAS: 1847-63-8)

Nafoxidine HCl is the hydrochloride salt of nafoxidine. Nafoxidine, structurally related to Tamoxifen, is a non-steroidal partial estrogen antagonist.

CAS 95167-41-2 DY131

DY131
(CAS: 95167-41-2)

DY131 is a novel selective agonist of ERRβ and ERRγ, which displays minimal activity at ERRα, ERα and ERβ at concentrations up to 30 μM. It could potentiate the...

Elacestrant S enantiomer dihydrochloride

Elacestrant S enantiomer dihydrochloride is an low activity enantiomer of elacestrant dihydrochloride. Elacestrant, also referred to RAD1901, is a selective and...

CAS 15183-37-6 Estetrol

Estetrol
(CAS: 15183-37-6)

Estetrol is a human steroid hormone produced by fetal liver from estradiol and estriol during pregnancy.

CAS 57-63-6 Ethinyl Estradiol

Ethinyl Estradiol
(CAS: 57-63-6)

Ethinyl Estradiol is a derivative of 17β-estradiol (E2), the major endogenous estrogen in humans. EE2 is an orally bioactive estrogen used in many formulations ...

CAS 486-66-8 Daidzein

Daidzein
(CAS: 486-66-8)

Daidzein belongs to the group of isoflavones.Daidzein can be converted to its end metabolite S-equol in some humans based on the presence of certain intestinal ...

CAS 112093-28-4 Endoxifen

Endoxifen
(CAS: 112093-28-4)

Endoxifen, a significant metamolite of Tamoxifen, is a regulator of estrogen receptor and could be effective in the treatment of estrogen-dependent breast cance...

CAS 50-27-1 Estriol

Estriol
(CAS: 50-27-1)

Estriol is a metabolite of 17β-estradiol with much lower biological activity. It is the primary estrogen found in the urine. Large quantities of estriol and est...

Chemical Structure

CAS 1365888-06-7 GDC-0810 (ARN-810)

Quick Inquiry

Verification code

Featured Items